Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06243003
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2024-01-24
Brief Title:
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Phase III Study to Evaluate the Safety and Efficacy of Hippocampal-avoidance Whole Brain Radiotherapy Followed by Stereotactic Radiotherapy for Extensive-stage Small Cell Lung Cancer With Baseline Brain Metastases
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases
Detailed Description:
At present the standard treatment for SCLC brain metastases is whole brain radiotherapy WBRT However WBRT is palliative in nature due to its low dose and poor long-term control rate of intracranial lesions At the same time with the advent of the era of immunotherapy a variety of PD-1PD-L1 monoclonal antibodies combined with chemotherapy have become the standard first-line treatment for extensive-stage SCLCES-SCLC Studies have shown that the survival time of SCLC patients with brain metastases is expected to be further prolonged in the era of chemotherapy and immunotherapy Therefore it is particularly important to further improve the control rate of intracranial lesions
It has been confirmed in previous studies that WBRT combined with stereotactic radiotherapy for visible intracranial lesions SRSSRT can effectively improve the control rate of intracranial lesions However most of the previous studies of WBRT combined with SRT for brain metastases did not include or only included a very small number of patients with SCLC Studies on thoracic radiotherapy for limited-stage small cell lung cancer have found that an increase in radiotherapy dose can significantly improve the prognosis of patients with SCLC which was previously considered to be highly radiosensitive It is reasonable to think that SRS combined with WBRT for SCLC brain metastases may improve the prognosis of patients
WBRT is known to cause severe cognitive impairment which has also led to the reluctance of some patients to undergo WBRT In the era of chemotherapy the NRG-CC001 study showed that Hippocampal avoidance WBRT HA-WBRT could better protect the cognitive function of patients without affecting the prognosis of patients The 2022 ASTRO guidelines have clearly recommended the use of hippocampal protection techniques in WBRT Considering the lack of previous literature on the use of SRS combined with WBRT in SCLC patients in the chemo-immunotherapy era The aim of this study is to adopt the dose fractionation of SRS combined with WBRT which has been proven to be safe in the treatment of brain metastases from NSCLC and to evaluate the safety of this treatment mode in SCLC patients with brain metastases receiving standard first-line chemoimmunotherapy
In summary this study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS in the first-line treatment of SCLC patients with baseline brain metastases who are suitable for SRS treatment during the standard first-line chemotherapy combined with immunotherapy
It has been confirmed in previous studies that WBRT combined with stereotactic radiotherapy for visible intracranial lesions SRSSRT can effectively improve the control rate of intracranial lesions However most of the previous studies of WBRT combined with SRT for brain metastases did not include or only included a very small number of patients with SCLC Studies on thoracic radiotherapy for limited-stage small cell lung cancer have found that an increase in radiotherapy dose can significantly improve the prognosis of patients with SCLC which was previously considered to be highly radiosensitive It is reasonable to think that SRS combined with WBRT for SCLC brain metastases may improve the prognosis of patients
WBRT is known to cause severe cognitive impairment which has also led to the reluctance of some patients to undergo WBRT In the era of chemotherapy the NRG-CC001 study showed that Hippocampal avoidance WBRT HA-WBRT could better protect the cognitive function of patients without affecting the prognosis of patients The 2022 ASTRO guidelines have clearly recommended the use of hippocampal protection techniques in WBRT Considering the lack of previous literature on the use of SRS combined with WBRT in SCLC patients in the chemo-immunotherapy era The aim of this study is to adopt the dose fractionation of SRS combined with WBRT which has been proven to be safe in the treatment of brain metastases from NSCLC and to evaluate the safety of this treatment mode in SCLC patients with brain metastases receiving standard first-line chemoimmunotherapy
In summary this study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS in the first-line treatment of SCLC patients with baseline brain metastases who are suitable for SRS treatment during the standard first-line chemotherapy combined with immunotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None